课题基金 / 基金详情

BG9719 & FUROSEMIDE FOR CONGESTIVE HEART FAILURE & RENAL INSUFFICIENCY

BG9719 & FUROSEMIDE FOR CONGESTIVE HEART FAILURE & RENAL INSUFFICIENCY
BG9719
批准号：
6265131
负责人：
D CRAIG BRATER
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6265131
关键词：
adenosine alpha antiadrenergic agent chronic renal failure clinical research clinical trial phase I congestive heart failure diuretics drug screening /evaluation furosemide heart disorder chemotherapy human subject human therapy evaluation kidney disorder chemotherapy

项目摘要

项目成果

D CRAIG BRATER的其他基金

相关文献

中文摘要
翻译
BG9719是一种有效和高选择性的腺苷A1受体拮抗剂，通过减少腺苷A1介导的近端和远端肾单位的钠重吸收而导致利尿。此外，BF9719拮抗腺苷A1对传入小动脉的收缩作用可阻断肾小管小球反馈环。因此，BG9719干扰了肾脏下调肾小球滤过的能力，以响应远端肾单位高盐负荷释放的腺苷，这进一步有助于其利尿作用。
英文摘要
BG9719 is a potent and highly selective adenosine A1-receptor antagonist that causes diuresis by reducing adenosine A1-mediated sodium reabsorption in both the proximal and distal nephron. In addition, antagonism of adenosine A1-mediated constriction of the afferent arteriole by BF9719 interrupts the tubuloglomerular feedback loop. Consequently, BG9719 interferes with the kidney's ability to down regulate glomerular filtration in response to adenosine released by a high salt load in the distal nephron, which further contributes to its diuretic effects.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Diuretics on Response to Torsemide in Patients with Congestive Heart Failure
General Clinical Research Ctr:Pharmacogenetics Core Supp
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE
MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE AND COMPARE